Trial Profile
A Retrospective study analysing outcomes of patients with relapsed/refractory Diffuse large B-Cell lymphoma treated with Ibrutinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 17 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology